The FDA has granted approval to Lifestar Pharma LLC’s ANDA for Atropine Sulfate Ophthalmic Solution, a generic alternative to branded versions used for myopia control. The approval is anticipated to leverage price discounting to intensify competitive pressure within the myopia management eye-drop market.